［1］Casulo C，O' Connor O，Shustov A，et al.T-cell lymphoma：Recent advances in characterization and new opportunities for treatment［J］.J Natl Cancer Inst，2017，109(2)：dtw248.
[2]Gooptu M，Rhoades R，Pro B.Current management of peripheral T-cell lymphomas［J］.Cancer Treat Res，2015，165：289-303.
[3]Barbarotta L，Hurley K.Romidepsin for the treatment of peripheral T-cell lymphoma［J］.J Adv Pract Oncol，2015，6(1)：22-36.
[4]Campo E，Steven H，Nancy L，et al.The 2008 WHO classification of lymphoid neoplasms and beyond：Evolving concepts and practical applications［J］.Blood，2011，117(19)：5019-5032.
[5]Mereu E，Pellegrino E，Scarfo I，et al.The heterogeneous landscape of ALK negative ALCL［J］.Oncotarget，2017，8(11)：18525-18536.
[6]Park S，Ko YH.Peripheral T-cell lymphoma in Asia［J］.Int J Hematol，2014，99(3)：227-239.
[7]Anderson JR，Armitage JO，Weisenburger DD，et al.Epidemiology of the non-Hodgkin's lymphomas：Distributions of the major subtypes differ by geographic locations.Non-Hodgkin's lymphoma classification project［J］.Ann Oncol，1998，9(7)：717-720.
[8]Vose J，Armitage J，Weisenburger D，et al.International T-cell lymphoma project.International peripheral T-cell and natural killer/T-cell lymphoma study：Pathology findings and clinical outcomes［J］.J Clin Oncol，2008，26(25)：4124-4130.
[9]Weisenburger DD，Savage KJ，Nancy LH，et al.Peripheral T-cell lymphoma，not otherwise specified：A report of 340 cases from the international peripheral T-cell lymphoma project［J］.Blood，2011，117(12)：3402-3408.
[10]Stefanovic A，Lossos TS.Rare PTCLs：Treatment lagging behind pathobiologic advances［J］.Oncology，2010，24(1)：101-102.
[11]Iqbal J，Wilcox R，Naushad H，et al.Genomic signatures in T-cell lymphoma：How can these improve precision in diagnosis and inform prognosis［J］?Blood Rev，2016，30(2)：89-100.
[12]Iqbal J，Weisenburger DD，Greiner TC，et al.Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma［J］.Blood，2010，115(5)：1026-1036.
[13]Agostinelli C，Piccaluga PP，Went P，et al.Peripheral T cell lymphoma，not otherwise specified：The stuff of genes，dreams and therapies［J］.J Clin Pathol，2008，61(11)：1160-1167.
[14]Moskowitz AJ，Lunning M，Horwitz SM，et al.How I treat the peripheral T cell lymphomas［J］.Blood，2014，123(17)：2636-2644.
[15]Zhou SY.The first-line treatment regimens of peripheral T-cell lymphomas［J］.Journal of Leukemia and Lymphoma，2015，22(9)：571-576.
[16]Sharma M，Pro B.Bone marrow transplantation for peripheral T-cell non-Hodgkins' lymphoma in first remission［J］.Curr Treat Options Oncol，2015，16(7)：34.
[17]Simon A，Peoch M，Casassus P，et al.Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma.Results of the randomized phase III trial GOELAMS-LTP95［J］.Br J Haematol，2010，151(2)：159-166.
[18]Schmitz N，Trümper L，Ziepert M，et al.Treatment and prognosis of mature T-cell and NK-cell lymphoma：An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group［J］.Blood，2010，116(18)：3418-3425.
[19]Zou D，Huang W，Liu H，et al.Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation［J］.Chin J Hematol，2015，36(6)：455-459.
[20]Yin J，Wei J，Xu JH，et al.Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma：Results of a comprehensive Meta-analysis［J］.Acta Haematol，2014，131(2)：114-125.
[21]D'amore F，Thomas R，Grete FL，et al.Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma：NLG-T-01［J］.J Clin Oncol，2012，30(25)：3093-3099.
[22]Kanakry JA，Kasamon YL，Ambinder RF，et al.Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma［J］.Biol Blood Marrow Transplant，2013，19(4)：602-606.
[23]Corradini P，Vitolo U，Rambaldi A，et al.Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma［J］.Leukemia，2014，28(9)：1885-1891.
[24]Mak V，Hamm J，Chhanabhai M，et al.Survival of patients with peripheral T-cell lymphoma after first relapse or progression：Spectrum of disease and rare long-term survivors［J］.J Clin Oncol，2013，31(16)：1970-1976.
[25]Damaj G，Gressin R，Bouabdallah K，et al.Results from a prospective open-label，phase II trial of bendamustine in refractory or relapsed T-cell lymphomas：The BENTLY trial［J］.J Clin Oncol，2013，31(1)：104-110.
[26]Park BB，Kim WS，Suh C，et al.Salvage chemotherapy of gemcitabine，dexamethasone，and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas：A consortium for improving survival of lymphoma (CISL) trial［J］.Ann Hematol，2015，94(11)：1845-1851.
[27]Broccoli A，Zinzani PL.Peripheral T-cell lymphoma，not otherwise aspecified［J］.Blood，2017，129(9)：1103-1112.
[28]Koch E，Story SK，Geskin LJ.Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy［J］.Leuk Lymphoma，2013，54(11)：2448-2451.
[29]West AC，Johnstone RW.New and emerging HDAC inhibitors for cancer treatment［J］.J Clin Invest，2014，124(1)：30-39.
[30]Piekarz RL，Frye R，Prince HM，et al.Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma［J］.Blood，2011，117(22)：5827-5834.
[31]Abutalib SA，Hari P，Phillips AA.T-cell lymphoma［J］.Clinical Manual of Blood and Bone Marrow Transplantation，2017：179-187.
[32]Moskowitz AJ，Horwitz SM.Targeting histone deacetylases in T-cell lymphoma［J］.Leuk Lymphoma，2017，58(6)：1306-1319.
[33]Cheah CY，Oki Y，Fanale MA，et al.Novel treatments for T-cell lymphoma［J］.Amsoc Clin Oncol Educ Book，2015，35(10)：e468-e478.
[34]Pro B，Advani R，Brice P，et al.Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma：Results of a phase II study［J］.J Clin Oncol，2012，30(18)：2190-2196.
[35]Bagot M.New targeted treatments for cutaneous T-cell lymphomas［J］.Indian J Dermatol，2017，62(2)：142-145.
[36]Enblad G，Hagberg H，Erlanson M，et al.A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas［J］.Blood，2004，103(8)：2920-2924.
[37]Galanina N，Petrich A，Nabhan C.The evolving role of lenalidomide in non-Hodgkin lymphoma［J］.Leuk Lymphoma，2016，57 (7)：1507-1516.
[38]Morschhauser F，Fitoussi O，Haioun C，et al.A phase 2，multicentre，single-arm，open-label study to evaluate the safety and efficacy of single agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma：The EXPECT trial［J］.Eur J Cancer，2013，49(13)：2869-2876.